Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Wednesday after the company reported mixed fourth-quarter financial results. What Happened: Recursion reported fourth-quarter ...